NIKA
NIKA PHARMACEUTICALS, INC
Next earnings Aug 12, 2026
$0.44
▲ 0.00%$0.44▼ -35.65%
over 1Y
L $0.20EODHDH $0.96
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-12.9%
1M+119.8%
3M-41.2%
YTD+16.8%
1Y-35.7%
Hold
Conviction
Horizon
Medium (3–12mo)
High return on equity (25.7%).
Revenue (FY2024) $0.00 · FY2024
NIKA PHARMACEUTICALS, INC shows $0.00 in FY2024 revenue, and 25.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$14.7K | -$3.18M | -$64.8K | -$95.8K | -$76.4K |
| Net income | -$14.7K | -$3.18M | -$64.8K | -$95.8K | -$76.4K |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$465M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-0.0%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt$319K
Net cash-$317K
Altman Z-Score246.45 safe
Piotroski F-Score1/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+2.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2024-11-01). Worth a closer look.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-05-12open ↗10-KPeriod ending 2025-12-312026-03-25open ↗10-QPeriod ending 2025-09-302025-11-07open ↗10-QPeriod ending 2025-06-302025-08-14open ↗10-QPeriod ending 2025-03-312025-05-13open ↗144Filing2025-04-16open ↗10-KPeriod ending 2024-12-312025-03-31open ↗4Period ending 2025-03-182025-03-19open ↗10-QPeriod ending 2024-09-302024-11-12open ↗10-Q/APeriod ending 2024-06-302024-11-01open ↗8-KPeriod ending 2024-10-022024-10-16open ↗UPLOADFiling2024-10-08open ↗
Frequently asked
- Is NIKA PHARMACEUTICALS, INC (NIKA) a buy?
- NIKA currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (25.7%).
- What is NIKA PHARMACEUTICALS, INC's quality score?
- NIKA scores 54/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001145604, latest 10-Q filed 2026-05-12) · EODHD · as of 6/23/2026, 1:56:05 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.